Unanswered questions of interest from the LITESPARK-004 trial
Lab Test says its fine, But Its not | Shared Story | False NegativeПодробнее
LITESPARK-004: 36 month follow-up of belzutifan in Von Hippel-Lindau syndromeПодробнее
Dr. Spigel on CheckMate-331 Trial for SCLCПодробнее
Belzutifan: Managed access treatment for Von Hippel-Lindau (VHL) diseaseПодробнее
COMPLETE study resultsПодробнее
Quest STD Awareness/Confidential TestingПодробнее
CheckMate 901: HRQoL findings of nivolumab and gemcitabine-cisplatin in UCПодробнее
LITESPARK-004: ESA use in VHL disease-associated RCCПодробнее
RCC Update from ESMO 2023Подробнее
January 4, 2025Подробнее
Expert witnesses explain digital evidence in Holly Hill murder trialПодробнее
Cohort 1 LITESPARK-003: belzutifan + cabozantinib 1L treatment for advanced RCCПодробнее
GALACTIC-HF Subgroup Analysis: Omecamtiv Mecarbil Effective Across Ethnic Groups | Dr David LanfearПодробнее
Highlights on belzutifan in previously treated advanced clear cell RCC: The LITESPARK-005 studyПодробнее
Dr. Jonasch on the Safety Profile of MK-6482 in Von Hippel-Lindau Disease–Associated RCCПодробнее
Eric Jonasch, MD, discusses the incidence of Von Hippel-Lindau Disease among RCC patientsПодробнее
Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCCПодробнее
Dr. Spigel on Checkmate 017- Phase III Trial for Nivolumab - Sarah CannonПодробнее
Dr. Brahmer on Impact of CheckMate-057 in NSCLCПодробнее
